Olema Pharmaceuticals, Inc.
NASDAQOlema Pharmaceuticals enters the week of October 18 with a fresh activist filing on its register, a stock down 33% in a month, and shorts holding nearly 20% of the float as the next data readout approaches in three weeks. The most newsworthy development on the register is BVF Partners filing a Schedule 13D on October 16, the day of this snapshot. BVF held 9.8% of the class as last…
Snapshot as of 18 Oct 2026
Olema Pharmaceuticals enters the week of October 18 with a fresh activist filing on its register, a stock down 33% in a month, and shorts holding nearly 20% of the float as the next data readout approaches in three…
OLMA heads into the autumn with one of the most heavily shorted profiles in clinical-stage biotech and a stock that has lost nearly 5% in a week, testing bulls whose conviction rests entirely on a single Phase 3…
Olema Pharmaceuticals heads into its August 14 earnings report carrying one of the heavier short burdens in clinical-stage biotech — and a Street consensus that disagrees sharply with the bears. Short interest is the…
OLMA heads into a defining two-week stretch carrying its heaviest short interest in months, a freshly beaten Q1 print, and a key oncology conference on the horizon — all while the stock trades down 13% over the past…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for OLMA — free to start on ORTEX.
Sign up for free →Open OLMA on ORTEX